Digital RESI Innovation Challenge

Vote for Me

Interested in Connecting? Please contact:
Keely Zipp
SVP. Corporate Development and Commercial Strategy

Message the company or request a 1:1 meeting here

Cybrexa Therapeutics is a private oncology-focused biotech developing a new class of therapeutics based on our alphalex™ platform.

The company anticipates its lead program, CBX-12 (alphalex™-exatecan), will enter Phase I/II in early 2021.  CBX-12 is an alphalex™ conjugate that includes the highly potent topoisomerase I inhibitor exatecan. CBX-12 was selected based on its strong efficacy and solid  safety profile demonstrated to date in preclinical studies. CBX-12 has potential synergy with PD-1 inhibitors and other immuno-oncology drugs. Cybrexa plans to publish preclinical data for CBX-12 in the first half of 2020 and to advance the program into the clinic in 2021, with clinical efficacy and safety data expected by 2022.